Keywords: Amgen, BioVex, M&A, Fourth-quarter 2010 financial results

Amgen buys BioVex for up to $1 billion; posts better-than-expected 4th-qrt 2010 results, with GAAP EPS growth at 11%

Article | 25 January 2011

Print This

Yesterday was a busy day for world leading biotech company Amgen (Nasdaq: AMGN) which, along with its expected financial results, ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in